Centogene Extends Collaboration with Takeda

Centogene recently reported that it had expanded its collaboration with Takeda Pharmaceutical Company Limited to detect patients with specific genetic disorders.

FREMONT, CA: Centogene N.V., a commercial-stage organization prioritizing rare diseases that turns real-world clinical and genetic data into actionable insights for patients, doctors, and pharmaceutical companies, recently reported that it has extended its collaboration with Takeda Pharmaceutical Company Limited to detect patients with specific genetic disorders.

CENTOGENE will continue to provide genetic testing to patients worldwide as part of the deal, which has been renewed until March 2022.

Andrin Oswald, M.D., CEO of CENTOGENE, said, "We are pleased to be extending our partnership with Takeda, which will allow us to continue diagnosing and connecting rare disease patients globally. There is still a lot of work to be done, but with each step, we are closer to bringing patients the life-saving medical solutions they need."

In January 2015, CENTOGENE signed an agreement with Shire Pharmaceuticals, a Takeda Pharmaceutical Company Limited subsidiary, to offer diagnostic testing abilities to improve the early diagnosis of patients with rare genetic diseases.

CENTOGENE specializes in rare disease diagnosis and research, converting real-world clinical and genetic data into actionable insights for patients, doctors, and pharmaceutical firms. Their mission is to use comprehensive rare disease knowledge, including epidemiological and clinical data and advanced biomarkers, to add rationality to treatment decisions and accelerate the production of new orphan drugs. As of September 30, 2020, CENTOGENE has created a global proprietary rare disease platform focused on the real-world data repository, which contains over 3.6 billion weighted data points from approximately 595,000 patients from over 120 countries.

The company's platform contains epidemiologic, phenotypic, and genetic data representing the worldwide population and a biobank of these patients' blood samples. CENTOGENE acknowledges that this is the only platform that analyses multi-level data comprehensively to enhance the understanding of rare genetic disorders, which will help to identify patients and improve the pharmaceutical partners' potential to bring orphan drugs to market. The company partnered with over 40 pharmaceutical partners representing over 45 rare diseases as of September 30, 2020.